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Abstract
Systemic lupus erythematosus (SLE) can affect various systems and organs. The most severe 
forms of the disease affect the kidneys, the central nervous system, and the heart. Cardiac 
and cardiovascular system diseases are inter alia caused by atherosclerosis, vasculitis, and 
thromboembolic events. Patients with SLE are at a higher risk of developing accelerated 
atherosclerosis. This process in SLE patients cannot be explained solely based on classical 
risk factors. Recently, some adipocytokines/adipokines have been indicated in the develop-
ment of atherosclerosis, inflammation, and immune processes. It has also been postulated 
that adipokines might regulate the immune response and hence the atherogenic process. In 
this work, the factors contributing to accelerated atherosclerosis in SLE patients with special 
respect to vasculitis/vascular injury are presented, and selected adipocytokines, that is leptin, 
resistin, and adiponectin, with their relation to atherosclerosis and SLE, are under discussion.
Keywords: systemic lupus erythematosus, pathogenesis, atherosclerosis, adipocytokines, 
associations
1. Introduction
Systemic lupus erythematosus (SLE) is an organ‐nonspecific autoimmune disease, more prev-
alent in young women than in men. It is characterized by periods of varying activity, some-
times even spontaneous remission. However, there can also be life‐threatening disease flares, 
especially in those patients who undergo incorrect treatment.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The pathogenesis of SLE involves different factors and generally speaking, complex gene‐
environment interactions [1, 2]. More specifically, abnormal lymphocyte count (T‐helper/T‐
suppressor cell quotient) and defects in T‐ and B‐lymphocyte functions should be emphasized. 
Ineffective clearance of apoptotic cells [3, 4] and of immune complexes containing host auto-
antigens and autoantibodies may also play a role in the development of SLE. Host lipids may 
contribute to the formation of immune complexes leading to the production of anticardiolipin 
antibodies [5]. Extracellular DNA molecules generated from apoptotic cells may also contrib-
ute to SLE as they promote the origin of anti‐DNA autoantibodies, which are characteristic of 
the disease [6–8]. It should be noted though that the cause of SLE is not fully known.
As already mentioned, SLE is an organ‐non‐specific autoimmune disease that can affect almost 
any organ or system; the most severe forms affect the kidneys, the central nervous system, 
and the heart. Cardiac and cardiovascular system involvement may result from atherosclero-
sis, vasculitis, and thromboembolic lesions that are known to be interrelated processes [9, 10].
Although SLE patients constitute a small proportion of the population dying from cardio-
vascular events, they tend to suffer from cardiovascular complications at a young age [11]. 
Previous studies on SLE‐related mortality revealed that early deaths were associated with 
disease activity and infections, whereas late deaths frequently resulted from atherosclerotic 
disease [12, 13]. It is noteworthy that these patients often suffer from accelerated atheroscle-
rosis, which is associated inter alia with lipid disturbances, vasculitis, and vascular injury. 
The latter result from the activity of autoantibodies and immune complexes, which, via the 
activation of the complement system, lead to autoimmune inflammation of the vascular wall. 
Long‐term side effects of lupus medications may also contribute to the development of car-
diovascular disease (CVD) [4, 7, 11, 14, 15].
2. Factors contributing to accelerated atherosclerosis in patients with SLE 
with special respect to vasculitis/vascular injury
Patients in early stages of SLE rarely exhibit cardiac manifestations. Nevertheless, in over 50% 
of severe cases, the heart is affected, and the patients suffer from pericarditis, myocarditis, 
Libman‐Sacks endocarditis, pulmonary hypertension, and coronary artery disease (CAD)—
the development of which is related to autoimmune processes characteristic of SLE [16].
Among CVD diagnosed in SLE patients, particular attention should be paid to angiopathy, 
which is due to a chronic inflammatory process within the vascular wall and underlies prema-
ture atherosclerosis [17–20]. Atherosclerosis is a progressive disease resulting from a multitude 
of factors, including altered composition of the extracellular matrix and activation of vascular 
smooth muscle cells in the arterial walls, which leads to atherosclerotic plaque formation.
Due to modern immunosuppressive therapy, prognosis in SLE patients has markedly improved. 
However, arterial disease (including CAD) and strokes still account for a large proportion of 
SLE‐related morbidity and mortality, while their pathogenesis has not been fully elucidated 
[21]. It has been estimated that the incidence of acute coronary syndromes is 50‐fold higher 
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in patients with SLE compared to the control [19, 22–25], while the CAD mortality rate ranges 
from 3.5 to 15.7% [26]. It should be noted that diagnostic imaging revealed subclinical athero-
sclerosis in 30–52% of SLE patients [24, 25, 27, 28].
The mechanisms of accelerated atherosclerosis in SLE patients are not fully understood and 
remain controversial. Its development cannot be accounted for based on traditional risk fac-
tors such as age, male sex, arterial hypertension, abnormalities in serum lipids, smoking, 
diabetes mellitus, obesity, and abnormal results of laboratory tests including high levels of 
C‐reactive protein (CPR), fibrinogen, and homocysteine [4, 11, 29–34]. Other causative factors 
that might promote accelerated atherosclerosis should also be considered [35].
It has been suggested that atherosclerosis could be caused by an immune reaction against 
autoantigens at the endothelial level, which include oxidized low‐density lipoprotein (LDL) 
and heat shock proteins (HSP) 60/65. Endothelial dysfunction plays a key role. It has also been 
speculated that immune mechanisms might be responsible for conversion of stable to instable 
plaque with resultant rupture [36].
Thus, it is not surprising that several autoimmune diseases, for example, SLE and antiphos-
pholipid syndrome, are considered to raise the risk of CAD [37]; nevertheless, the precise 
mechanism is yet to be defined [38]. Multiple researchers believe that atherosclerosis is asso-
ciated with immune responses [37, 39, 40]; it should be emphasized though that considering 
atherosclerosis as a solely autoimmune condition would be an oversimplification since meta-
bolic disorders and hemodynamic factors are also involved in its development [41].
Although there is a lot of evidence that inflammation plays a central role in atherosclerosis, its 
pathogenesis is also associated with other risk factors often connected with SLE, that is arterial 
hypertension (especially renal hypertension), prolonged exposure to high doses of glucocorti-
coids (which, apart from having a beneficial anti‐inflammatory action, also influence blood pres-
sure and glucose metabolism), lupus‐associated antiphospholipid syndrome, diabetes mellitus, 
and hypercholesterolemia [23, 25]. It should be noted that a regimen of ≤ 10 mg prednisone daily 
is considered safe in this respect [25]; however, the problem of metabolic disorders seen in SLE 
patients and its relation to glucocorticoid doses has not been satisfactorily elucidated. Contrary 
to steroids, antimalarial drugs used in SLE patients have a beneficial effect on their lipid profile.
Patients with SLE also exhibit other metabolic disturbances that may promote accelerated ath-
erosclerosis and accelerated CAD. These include hypertriglyceridemia, high homocysteine 
levels, and early menopause [25].
The multifactorial etiology of atherosclerosis makes it difficult to unambiguously determine 
why SLE patients develop atherosclerotic lesions earlier in life and more frequently than the 
general population. Researchers are often confronted with inconsistent results [23, 42]; hence, 
it has been suggested SLE might be considered an independent risk factor for atherosclerosis 
including CAD [24, 43–45] and CVD [23].
The factors underlying the atherosclerotic process undoubtedly comprise pro‐inflammatory cyto-
kines, antiphospholipid antibodies, antiendothelial cell antibodies (AECAs), and  antineutrophil 
cytoplasmic antibodies (ANCAs), all acting directly on blood vessels or forming deposits of 
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immune complexes. Monocyte chemotactic protein‐1 (MCP‐1) [7] is also involved; its higher con-
centrations were revealed in the blood of our study participants with mild‐to‐moderate SLE [46]. 
Other researchers investigated the relationships between atherosclerotic plaques in the carotid 
arteries, antiphospholipid antibodies, and peripheral blood leukocyte count, an established indi-
cator of inflammation [25]. There is also a spectrum of vascular abnormalities in SLE, resulting 
from adverse effects of several drugs or induced by infections, etc. [15].
It is important to note that vascular injury may develop not only due to an inflammatory 
condition but also as a result of non‐inflammatory factors including environmental influences 
(toxicity, medication, or micro‐organisms), neoplastic process, etc. [14]. Vascular disease in 
SLE patients can occur due to a combination of different pathological processes, for exam-
ple, atherosclerosis, clotting disorders, and systemic vasculitis associated with vascular wall 
injury (especially endothelial dysfunction), caused by an autoimmune process [24, 28].
SLE patients most typically exhibit cutaneous vasculitis; systemic vasculitis develops in 10–18% 
of these patients and, as a life‐threatening condition, may require aggressive therapy [14, 15].
Recently, it has been suggested that adipokines might play a causative role in the develop-
ment of atherosclerosis, inflammatory, and immune processes [47]. These factors, secreted by 
the white adipose tissue, have autocrine‐like actions, locally affecting adipocyte biology. They 
also act as endocrine factors that regulate systemic processes, for example, food intake, insu-
lin sensitivity, bone growth and energy homeostasis, and affect development of obesity and 
metabolic syndrome [40, 48]. Adipokines have been indicated in the link between immune 
response and atherosclerotic process [49].
Since patients with SLE develop metabolic syndrome, insulin resistance, dyslipidemia, or 
hypertension more frequently than the general population [50–54], the interest in the adipose 
tissue is justified in the group of rheumatic diseases [55, 56]. Identification of mechanisms 
common to inflammation and CVD might be of considerable interest especially in the context 
SLE, which is, potentially, a model disease for gaining a deeper insight into such mechanisms 
[13]. Generally, the relationship of adipokines to inflammation and coronary atherosclerosis 
in patients with SLE has not been fully elucidated [57]; for example, it has not been deter-
mined whether adiponectin concentrations in SLE result from metabolic disorders or inflam-
matory processes and nor has it been determined whether adipokine abnormalities associated 
with connective tissue diseases contribute to disease development or are caused by inflamma-
tion induced by other pro‐inflammatory factors [58].
3. Adipocytokines and their relation to atherosclerosis and systemic 
lupus erythematosus
White adipose tissue is a loose connective tissue composed of adipocytes and also containing 
adipocyte precursors, immune system cells fibroblasts, and other cell types [59]. Previously, 
this tissue had been considered an energy store (triglycerides) but now it is known to pro-
duce a number of biologically active substances that act at autocrine, paracrine, and endocrine 
levels. They regulate homeostasis through regulation of food intake, energy balance, lipid, 
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and carbohydrate metabolism. They also modulate the insulin effects, angiogenesis, and vas-
cular remodeling, regulate arterial pressure, affect inflammatory processes as well as associ-
ated immune response, and have metabolic effects including an impact on the development of 
atherosclerosis [47, 50, 57, 59–63]. Since the structure of these substances resembles that of the 
cytokine family, they have been referred to as adipocytokines or adipokines [60]. Their mul-
tifunctionality underlies the relationship between white adipose tissue, metabolic disorders, 
and autoimmune diseases [59]. Actions of selected adipokines are summarized in Table 1.
The role of adipokines in atherosclerosis deserves particular attention as they modulate 
inflammatory processes and initiate its development [60]. Adipokines may constitute a link 
between impaired insulin sensitivity, obesity, chronic inflammation, and atherosclerosis in 
patients with SLE [57, 64]. It has been speculated that altered serum/plasma levels of adipo-
kines in SLE might be related to coronary atherosclerosis, insulin resistance, and the inflam-
matory process [57]; however, these correlations need to be further explored and documented 
[65]. A deep insight into the mechanisms of adipokine actions would help develop new thera-
pies—also for autoimmune disorders [58, 66].
It is assumed that resistin or leptin have pro‐inflammatory and proatherosclerotic effects; they 
have also been implicated in insulin resistance [57, 67]. Conversely, adiponectin has an inverse 
association with inflammatory states, atherosclerosis, and insulin resistance [68]; hence, indepen-
dent of traditional risk factors, low level of adiponectin might also contribute to the development 
of the abovementioned diseases [57, 69]. However, other studies did not confirm these causative 
associations [69–71] with respect to total adiponectin levels but only to some adiponectin iso-
forms determined in the serum [69]. The reported research results are therefore inconsistent.
Resistin plays an important role in the inflammatory process, but its amount in adipocytes is 
quite small. Greater resistin concentrations have been found in adipose tissue monocytes and 
macrophages and peripheral blood monocytes [72, 73]. It is also present in neutrophils and 
is capable of inducing the production of IL‐6 and TNFα [42, 74–76]. These facts may indicate 
pro‐inflammatory properties of resistin [73]. Patients with severe inflammatory disease exhibit 
significant increases in plasma resistin [77]. It is also noteworthy that endothelial cells exhibit 
sensitivity to resistin.
Resistin Adiponectin Leptin
Obesity Obesity Insulin resistance
Type 2 diabetes mellitus Rheumatoid arthritis Rheumatoid arthritis
Sleep apnea Degenerative joint disease Degenerative joint disease
Chronic kidney disease Diabetes mellitus Hepatitis
Atherosclerosis Liver damage Inflammatory bowel disease
Arthritis Cardiovascular disease Sepsis
Nonalcoholic fatty liver disease Encephalomyelitis
Cardiovascular disease
Table 1. Relationships between selected adipokines and disease processes in humans.
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Although the role of resistin in SLE has not been fully determined [57, 58], its concentra-
tions in the peripheral blood of SLE patients are elevated and have been found to correlate 
with inflammatory markers, glomerular filtration rate, and glucocorticoid therapy [75, 78]. 
However, other studies did not reveal significant differences in serum resistin between 
patients with SLE and control participants [78]. Hence, reports on resistin levels in SLE 
patients are not consistent and its role remains to be elucidated.
It has been argued that resistin concentrations might be predictive of coronary atheroscle-
rosis, acute coronary events, and associated mortality [74, 78, 79]. It has been hypothesized 
that resistin secreted from macrophages in atheromas could affect vascular cell function and 
promote atherosclerosis [80]. Furthermore, it has been suggested that the levels of serum 
resistin might help determine the severity of myocardial ischemia [81], and its reduction 
could possibly reduce the risk for CVD [47]. It has also been speculated that this adipokine 
is more related to the inflammatory process and atherosclerosis than to obesity and insulin 
resistance [47].
Plasma leptin is known to be proportional to the total amount of adipose tissue, and 
therefore it is directly related to obesity and associated CVDs including atherosclerosis. 
Leptin exerts its atherogenic effects via induction of endothelial dysfunction, stimulation 
of inflammatory response, oxidative stress, platelet aggregation, migration, hypertrophy, 
and proliferation of vascular smooth muscle cells [82]. It regulates blood pressure and 
this is probably independent of body adiposity [83]. Plasma leptin concentration corre-
lates with markers of subclinical atherosclerosis such as extracranial carotid intima‐media 
thickness and coronary artery calcification. Beltowski [82] speculates that inhibition of 
leptin activity might slow down the progression of atherosclerosis in obese individuals 
with hyperleptinemia.
There are also data on the involvement of leptin in the immune response [77] and its modu-
latory effect on monocytes/macrophages, neutrophils, basophils, eosinophils, natural killer 
cells (NK), and dendritic cells [63, 84]. It has also been indicated in lymphocyte reactivity [85]. 
As already mentioned, leptin is considered a pro‐inflammatory adipokine; therefore, changes 
in its plasma levels observed in SLE patients are not surprising. Leptin modulates the cardio-
vascular risk in these patients [86], and several authors have suggested that the adipokine 
might act as an independent risk factor for CVD [68].
Patients with SLE had higher plasma leptin compared to the control [49, 57, 87, 88], but clini-
cal relevance of leptin level changes in autoimmune disorders remains unclear [87]. Several 
researchers believe that leptin is involved in the pathogenesis thereof [88, 89]. The evalua-
tion of leptin concentrations in SLE patients with correction for BMI (body mass index) also 
revealed higher levels in the study group [42]. However, other authors concluded that leptin 
levels in SLE patients were lower or comparable to those found in healthy controls [90, 91].
Adiponectin, the major product of adipocytes, functions as an autocrine/paracrine factor 
within the adipose tissue and exerts endocrine effects on distant tissues thus influencing 
whole‐body metabolism [92].
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The role of adiponectin in SLE remains controversial. Several researchers observed an 
increase in adiponectin concentration in SLE patients [57, 91], while others did not find dif-
ferences compared to the control [50, 58]. However, plasma adiponectin levels tend to be 
higher in patients with renal SLE in comparison to healthy controls and patients with non‐
renal SLE [93].
Although the role of adiponectin in SLE pathogenesis has not been fully elucidated [86], 
higher local and/or systemic concentrations of this adipokine have been noted in chronic 
inflammatory conditions including SLE [94]. Nevertheless, processes leading to adiponec-
tin levels elevation in chronic inflammatory/autoimmune diseases are still to be clarified 
[94].
The significance of adiponectin in atherosclerosis also needs clarification [72]. It was postu-
lated that the anti‐inflammatory effects of adiponectin were associated with the inhibition 
of pro‐inflammatory cytokines, decreased leukocyte adhesion, and enhanced production of 
anti‐inflammatory cytokines [95]. Adiponectin mediates inhibition of macrophage phago-
cytosis and decreases the production of IL‐6 and TNF. It strongly inhibits B‐lymphopoiesis, 
reduces T‐lymphocyte response, and induces the production of anti‐inflammatory agents 
(e.g., IL‐10) in human monocytes, macrophages, and dendritic cells [62, 63]. Adiponectin 
also suppresses monocyte adhesion to endothelial cells as well as migration and prolifera-
tion of smooth muscle cells [30]. Hence, it may exert a beneficial effect in the metabolic 
syndrome and coronary heart disease. Low adiponectin concentrations have been found to 
enhance insulin resistance and the risk for coronary heart disease. It is noteworthy, though, 
that, contrary to its protective role with respect to obesity and vascular disease, adiponectin 
seems to have pro‐inflammatory effects in joint diseases [58, 62, 63].
Summing up, it should be noted that metabolic disorders frequently seen in patients with SLE 
might result from the disease itself or genetic influences/long‐term treatment. Patients with 
SLE also tend to more frequently develop a classic metabolic disease, that is obesity, which 
is associated with chronic, although not severe, inflammatory conditions. The latter has an 
impact on insulin resistance‐related type 2 diabetes as well as on atherosclerosis and ischemic 
heart disease.
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